-
Integra LifeSciences founder Dr. Richard Caruso dies
Richard Caruso, PhD, founder, former CEO and former chair of Integra lifeSciences, has died, the company said Aug. 16. -
Dr. Randal Mills named Aziyo Biologics' CEO
Randal "Randy" Mills, PhD, co-founder of Aziyo Biologics, assumed the role of president and CEO of the company. -
Orthofix Medical partners with biologics company
Orthofix and CGBio partnered for the development and commercialization of Novosis, a bone growth material and regenerative products.
-
AlloSource CEO to retire
AlloSource's president and CEO, Tom Cycyota, plans to retire after leading the biologics company for 22 years. -
AOSSM honors injectable bone substitute
Anika Therapeutics earned the American Orthopedic Society for Sports Medicine's ACE award for cutting-edge innovation for its Tactoset product. -
5 orthopedic surgeons part of scientific board for regenerative medicine company
Five orthopedic surgeons are part of a new regenerative medicine scientific advisory board for Mimedx. -
Dr. Tomas Ellis debuts Orthofix orthopedic autograft substitute
Orthofix's Virtuos Lyograft allograft was debuted by neurosurgeon Thomas Ellis, MD.
-
Biologic medtech company names new CEO
NovaBone, a biologic medtech company focused on orthopedic and dental products, hired Brian Carlisle as CEO. -
8 developments in regenerative medicine
From a notable stem cell study to newly launched products, here are eight updates in regenerative orthopedic medicine: -
Ossifix Orthopedics to launch demineralized bone matrix
Ossifix Orthopedics will launch its demineralized bone matrix, made from 100 percent human bone tissue in August. -
New Jersey pediatric practice adds biologic ACL treatment
The Pediatric Orthopedic Center in Cedar Knolls, N.J., became the first pediatric-only orthopedic practice in its region to add the Bear implant for ACL restoration.
-
New drug could help repair spinal cord injury in patients
Scientists in the U.K. have found that a new drug being tested for cancer therapy may also be able to reduce damage in patients with spinal cord injuries. -
Spiderwort secures $13.2M to advance spinal cord scaffold
Spiderwort, a startup developing cellulose-based tissue scaffolding to treat acute spinal cord injuries, has secured $13.2 million through a series A financing round, the company said July 12. -
How is orthobiologics developing in 2022? 4 observations
Regenerative medicine in orthopedics has developed in the first half of 2022, and many surgeons have a positive outlook toward it. -
AlloSource adds allograft for spine, orthopedics
AlloSource added the AlloFuse microfibers demineralized bone allograft to its product line. -
Orthobiologics company launches cortical allograft product line
Istos Biologics launched the Influx Fibrant line of 100 percent cortical allograft products. -
Aziyo Biologics names Dr. Randal Mills interim president and CEO
Aziyo Biologics co-founder Randal Mills, PhD, was named interim president and CEO. -
Theradaptive's regenerative implant earns 3rd breakthrough designation for spinal fusion
Theradaptive's OsteoAdapt SP implant received its third FDA breakthrough designation. -
Cincinnati physician leads stem cell trial for back pain patients
A Cincinnati pain management physician led the first prospective controlled trial in the world on treating chronic back pain with stem cells, with about 70 percent of participants seeing positive results. -
Orthobiologics company gets clearance for bone marrow aspirate system
Royal Biologics received FDA approval for its MAXX-BMC bone marrow aspirate concentration system.